ImmuPharma's market cap is currently ―. The company's EPS TTM is p-0.009; its P/E ratio is -2.77; ImmuPharma is scheduled to report earnings on May 23, 2024, and the estimated EPS forecast is p―. See an overview of income statement, balance sheet, and cash flow financials.

	Jun 22	Dec 21	Jun 21	Dec 20	Jun 20
Income Statement	-
Total Revenue	-	-	-	-	-
Gross Profit	-	-	-	-	-
EBIT	-	-	-	-	-
EBITDA	-	-	-	-	-
Net Income Common Stockholders	-	-	-	-	-
Balance Sheet	-
Cash, Cash Equivalents and Short-Term Investments	£ 170.92K	£ 1.60M	£ 4.25M	£ 5.86M	£ 2.71M
Total Assets	£ 2.88M	£ 6.00M	£ 7.08M	£ 10.92M	£ 7.98M
Total Debt	£ 230.00	£ 700.00	£ 656.73K	£ 641.84K	£ 1.87M
Net Debt	£ -170.69K	£ -1.60M	£ -3.59M	£ -5.22M	£ -848.09K
Total Liabilities	£ 858.52K	£ 1.58M	£ 1.77M	£ 1.26M	£ 2.10M
Stockholders Equity	£ 2.02M	£ 4.41M	£ 5.31M	£ 9.65M	£ 5.88M
Cash Flow	-
Free Cash Flow	-	-	-	-	-
Operating Cash Flow	-	-	-	-	-
Investing Cash Flow	-	-	-	-	-
Financing Cash Flow	-	-	-	-	-

Currency in GBP

ImmuPharma Earnings and Revenue History

Income Statement >

ImmuPharma Debt to Assets

Balance Sheet >

ImmuPharma Cash Flow

Cash Flow >

ImmuPharma Forecast EPS vs Actual EPS

Earnings >

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing